<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399163</url>
  </required_header>
  <id_info>
    <org_study_id>203160</org_study_id>
    <nct_id>NCT02399163</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral Hygiene Products in an In Situ Caries Model</brief_title>
  <official_title>Clinical Evaluation of Oral Hygiene Products in an In Situ Caries Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate and compare the potential anti-caries efficacy of a test regimen:
      placebo (fluoride free) toothpaste (twice daily use) plus fluoride mouthwash (once daily
      use), in comparison with brushing with a placebo toothpaste alone (twice daily use), to
      remineralize previously demineralized enamel specimens, as measured by Surface MicroHardness
      Recovery (%SMHR).

      This will be a single center, randomized, laboratory analyst blinded, placebo, four
      treatment, cross-over study in healthy participants. Participants will be assessed at
      baseline and at the beginning and end of each treatment visit to monitor clinical efficacy
      and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Surface Microhardness Recovery (%SMHR) of Placebo Dentifrice/Fluoride Rinse Compared to Placebo Dentifrice/No Rinse</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was performed ex-vivo and determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents re-hardening of enamel surface. % SMH recovery was calculated from indentation length (micrometer [μm]) of sound enamel specimen at baseline(B), indentation length (μm) after in vitro demineralization(D1), indentation length (μm) after intra-oral exposure (R): [D1-R/D1-B]*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Surface Microhardness Recovery (SMHR) of Placebo Dentifrice/Fluoride Rinse, Placebo Dentifrice/No Rinse, Fluoride Dentifrice/No Rinse and Fluoride Dentifrice/Fluoride Rinse</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was performed ex-vivo and determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. % SMH recovery was calculated from indentation length (micrometer [μm]) of sound enamel specimen at baseline(B), indentation length (μm) after in vitro demineralization(D1), indentation length (μm) after intra-oral exposure (R): [D1-R/D1-B]*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enamel Fluoride Uptake</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling samples was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Saliva Fluoride Concentration From Baseline (Pre-treatment) to Day 14</measure>
    <time_frame>Baseline to Day14</time_frame>
    <description>Fluoride concentration in saliva was measured after collecting saliva samples at the following time points: - at Day 1 baseline prior to supervised treatment. - at day 1 post supervised treatment at site. - at Day 14 post treatment. The amount of fluoride in the samples was calculated based on the amount of fluoride divided by the volume of the sample and expressed as μg/mL of sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Saliva Fluoride Concentration From Baseline (Post-treatment) to Day 14</measure>
    <time_frame>Baseline up to Day 14</time_frame>
    <description>Fluoride concentration in saliva was measured after collecting saliva samples at the following time points: - at Day 1 post supervised treatment at site. - at Day 14 post treatment. The amount of fluoride in the samples was calculated based on the amount of fluoride divided by the volume of the sample and expressed as μg/mL of sample.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>Placebo dentifrice/Fluoride rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dentifrice/No rinse</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoride dentifrice/No rinse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoride dentifrice/Fluoride rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoride free toothpaste</intervention_name>
    <description>Brushing with fluoride free toothpaste</description>
    <arm_group_label>Placebo dentifrice/No rinse</arm_group_label>
    <arm_group_label>Placebo dentifrice/Fluoride rinse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoride toothpaste</intervention_name>
    <description>Brushing with fluoride containing toothpaste</description>
    <arm_group_label>Fluoride dentifrice/Fluoride rinse</arm_group_label>
    <arm_group_label>Fluoride dentifrice/No rinse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoride mouthwash</intervention_name>
    <description>Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in &quot;Placebo dentifrice/Fluoride rinse&quot; arm and in &quot;Fluoride dentifrice/Fluoride rinse&quot; arm</description>
    <arm_group_label>Fluoride dentifrice/Fluoride rinse</arm_group_label>
    <arm_group_label>Placebo dentifrice/Fluoride rinse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18 and 85 years inclusive

          2. Understands and is willing, able and likely to comply with all study procedures and
             restrictions

          3. Good general and mental health with, in the opinion of the investigator or medically
             qualified designee:

               -  No clinically significant and relevant abnormalities in medical history or upon
                  oral examination.

               -  Absence of any condition that could affect the participant's safety or well-being
                  or their ability to understand and follow study procedures and requirements

          4. Currently living in the Indianapolis, Indiana area and has not had a professional
             fluoride treatment within 14 days of the first treatment visit

          5. Currently wearing a removable mandibular partial denture with sufficient room in one
             posterior buccal flange areas to accommodate two enamel specimens

          6. Willing to have their denture modified to accommodate enamel test specimens and
             willing and capable of wearing their removable mandibular partial dentures 24 hours
             per day during the experimental periods

          7. Have a salivary flow rate in the range of normal values (un-stimulated whole saliva
             flow rate ≥ 0.2 milliliter (mL)/minute; gum base stimulated whole saliva flow rate ≥
             0.8 mL/minute).

        Exclusion Criteria:

          1. Pregnant or breast feeding women

          2. Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients

          3. Currently taking antibiotics or have taken antibiotics in the two weeks prior to the
             screening visit.

          4. Taking or have taken a bisphosphonate drug for treatment of osteoporosis.

          5. Participation in another GSKCH investigational dental product study within seven days
             of first study treatment.

          6. Previous participation in this study.

          7. Recent history (within the last year) of alcohol or other substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <results_first_submitted>April 4, 2016</results_first_submitted>
  <results_first_submitted_qc>April 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2016</results_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at one center in United States of America.</recruitment_details>
      <pre_assignment_details>A total of 80 participants were screened. Of the 80 participants, 62 were randomized and 53 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>In this cross-over study, participants were randomized to receive each of following treatments:
Fluoride dentifrice/Fluoride rinse
Placebo dentifrice/Fluoride rinse
Fluoride dentifrice/No rinse
Placebo dentifrice/No rinse</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Participant</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Participants</title>
          <description>All randomized participants were evaluated for baseline characteristics</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Surface Microhardness Recovery (%SMHR) of Placebo Dentifrice/Fluoride Rinse Compared to Placebo Dentifrice/No Rinse</title>
        <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was performed ex-vivo and determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents re-hardening of enamel surface. % SMH recovery was calculated from indentation length (micrometer [μm]) of sound enamel specimen at baseline(B), indentation length (μm) after in vitro demineralization(D1), indentation length (μm) after intra-oral exposure (R): [D1-R/D1-B]*100.</description>
        <time_frame>Baseline to 14 days</time_frame>
        <population>Per-protocol (PP) population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 parts per million (ppm) of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Surface Microhardness Recovery (%SMHR) of Placebo Dentifrice/Fluoride Rinse Compared to Placebo Dentifrice/No Rinse</title>
          <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was performed ex-vivo and determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents re-hardening of enamel surface. % SMH recovery was calculated from indentation length (micrometer [μm]) of sound enamel specimen at baseline(B), indentation length (μm) after in vitro demineralization(D1), indentation length (μm) after intra-oral exposure (R): [D1-R/D1-B]*100.</description>
          <population>Per-protocol (PP) population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
          <units>% SMHR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.48" spread="16.088"/>
                    <measurement group_id="O2" value="8.09" spread="25.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>From ANOVA: participant (random), treatment (fixed), period (fixed)</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>16.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.061</ci_lower_limit>
            <ci_upper_limit>22.454</ci_upper_limit>
            <estimate_desc>Difference is Placebo dentifrice/Fluoride rinse minus Placebo dentifrice/No rinse such that a positive difference implies a larger response value for the Placebo dentifrice/Fluoride rinse.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Surface Microhardness Recovery (SMHR) of Placebo Dentifrice/Fluoride Rinse, Placebo Dentifrice/No Rinse, Fluoride Dentifrice/No Rinse and Fluoride Dentifrice/Fluoride Rinse</title>
        <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was performed ex-vivo and determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. % SMH recovery was calculated from indentation length (micrometer [μm]) of sound enamel specimen at baseline(B), indentation length (μm) after in vitro demineralization(D1), indentation length (μm) after intra-oral exposure (R): [D1-R/D1-B]*100.</description>
        <time_frame>Baseline to 14 days</time_frame>
        <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
          </group>
          <group group_id="O3">
            <title>Fluoride Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O4">
            <title>Fluoride Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Surface Microhardness Recovery (SMHR) of Placebo Dentifrice/Fluoride Rinse, Placebo Dentifrice/No Rinse, Fluoride Dentifrice/No Rinse and Fluoride Dentifrice/Fluoride Rinse</title>
          <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was performed ex-vivo and determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. % SMH recovery was calculated from indentation length (micrometer [μm]) of sound enamel specimen at baseline(B), indentation length (μm) after in vitro demineralization(D1), indentation length (μm) after intra-oral exposure (R): [D1-R/D1-B]*100.</description>
          <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
          <units>% SMHR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.48" spread="16.088"/>
                    <measurement group_id="O2" value="8.09" spread="25.892"/>
                    <measurement group_id="O3" value="28.36" spread="21.037"/>
                    <measurement group_id="O4" value="30.01" spread="18.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enamel Fluoride Uptake</title>
        <description>The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling samples was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm^2).</description>
        <time_frame>Baseline to 14 days</time_frame>
        <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
          </group>
          <group group_id="O3">
            <title>Fluoride Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O4">
            <title>Fluoride Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.</description>
          </group>
        </group_list>
        <measure>
          <title>Enamel Fluoride Uptake</title>
          <description>The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling samples was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm^2).</description>
          <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
          <units>microgram per square centimeter(μg/cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="3.016"/>
                    <measurement group_id="O2" value="1.60" spread="0.670"/>
                    <measurement group_id="O3" value="8.01" spread="3.925"/>
                    <measurement group_id="O4" value="9.97" spread="4.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Saliva Fluoride Concentration From Baseline (Pre-treatment) to Day 14</title>
        <description>Fluoride concentration in saliva was measured after collecting saliva samples at the following time points: - at Day 1 baseline prior to supervised treatment. - at day 1 post supervised treatment at site. - at Day 14 post treatment. The amount of fluoride in the samples was calculated based on the amount of fluoride divided by the volume of the sample and expressed as μg/mL of sample.</description>
        <time_frame>Baseline to Day14</time_frame>
        <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
          </group>
          <group group_id="O3">
            <title>Fluoride Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O4">
            <title>Fluoride Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Saliva Fluoride Concentration From Baseline (Pre-treatment) to Day 14</title>
          <description>Fluoride concentration in saliva was measured after collecting saliva samples at the following time points: - at Day 1 baseline prior to supervised treatment. - at day 1 post supervised treatment at site. - at Day 14 post treatment. The amount of fluoride in the samples was calculated based on the amount of fluoride divided by the volume of the sample and expressed as μg/mL of sample.</description>
          <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
          <units>microgram per mililitre(μg/mL )</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.317"/>
                    <measurement group_id="O2" value="-0.01" spread="0.030"/>
                    <measurement group_id="O3" value="0.00" spread="0.245"/>
                    <measurement group_id="O4" value="0.06" spread="0.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Saliva Fluoride Concentration From Baseline (Post-treatment) to Day 14</title>
        <description>Fluoride concentration in saliva was measured after collecting saliva samples at the following time points: - at Day 1 post supervised treatment at site. - at Day 14 post treatment. The amount of fluoride in the samples was calculated based on the amount of fluoride divided by the volume of the sample and expressed as μg/mL of sample.</description>
        <time_frame>Baseline up to Day 14</time_frame>
        <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
          </group>
          <group group_id="O3">
            <title>Fluoride Dentifrice/No Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride</description>
          </group>
          <group group_id="O4">
            <title>Fluoride Dentifrice/Fluoride Rinse</title>
            <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Saliva Fluoride Concentration From Baseline (Post-treatment) to Day 14</title>
          <description>Fluoride concentration in saliva was measured after collecting saliva samples at the following time points: - at Day 1 post supervised treatment at site. - at Day 14 post treatment. The amount of fluoride in the samples was calculated based on the amount of fluoride divided by the volume of the sample and expressed as μg/mL of sample.</description>
          <population>PP population included all participants who were randomized into the study, received at least one dose of study product, had at least one post-baseline efficacy assessment and had no protocol violations deemed to affect efficacy during the study.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.08" spread="9.743"/>
                    <measurement group_id="O2" value="0.05" spread="0.045"/>
                    <measurement group_id="O3" value="8.62" spread="6.892"/>
                    <measurement group_id="O4" value="13.81" spread="10.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Dentifrice/Fluoride Rinse</title>
          <description>Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride</description>
        </group>
        <group group_id="E2">
          <title>Placebo Dentifrice/No Rinse</title>
          <description>Twice daily brushing with a non-fluoride (placebo) toothpaste</description>
        </group>
        <group group_id="E3">
          <title>Fluoride Dentifrice/No Rinse</title>
          <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride</description>
        </group>
        <group group_id="E4">
          <title>Fluoride Dentifrice/Fluoride Rinse</title>
          <description>Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tongue Geographic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lip Dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oral Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tongue Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gingival Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gingival Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gingival Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gingival Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lip Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>ORAL MUCOSAL ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>TRAUMATIC OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJURY ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MOUTH INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>TONGUE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>SMEAR CERVIX ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>THROAT TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

